Bioluminescence imaging of invasive intracranial xenografts: implications for translational research and targeted therapeutics of brain tumors

• Published in: Neurosurgical review 2010-10, Vol.33 (4), p.385-394
• Main Authors: Dinca, Eduard B., Voicu, Ramona V., Ciurea, Alexandru V.
• Format: Article
• Language: English
• Subjects: Animals; Animals, Genetically Modified; Antineoplastic Agents - therapeutic use; Brain Neoplasms - drug therapy; Brain Neoplasms - pathology; Cell Line, Tumor; Humans; Kaplan-Meier Estimate; Luminescence; Medicine; Medicine & Public Health; Mice; Mice, Nude; Neoplasm Transplantation - pathology; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - pathology; Neurosurgery; Review; Translational Medical Research; Transplantation, Heterologous
• ISSN: 0344-5607; 1437-2320
• DOI: 10.1007/s10143-010-0275-4

Despite decades of study, the etiology of brain cancer remains elusive. However, extensive molecular characterization of primary brain tumors has been accomplished, outlining recurrent features that are proving useful for devising targeted therapies. There are far too few patients available for comparing the efficacy of therapeutic combinations, especially when variations in dosing, frequency, and sequencing are taken into account. Consequently, there is a substantial need for increasing preclinical testing throughput using clinically relevant models. We review luminescent optical imaging for its potential in facilitating in vivo assessment of intracranial tumor growth and response to therapy in rodent orthotopic xenograft models of primary brain malignancies. We review the rationale behind the need of an in vivo model, why orthotopic tumor models displaying an invasive phenotype may be a superior choice when compared to flank-implanted tumors, and what advantages may be drawn from the use of modified cells, suitable for sequential monitoring by in vivo optical imaging. Studies show that luminescent signal correlates highly both with tumor burden and Kaplan–Meier survival curves of rodents bearing intracranial xenografts. We conclude that bioluminescent imaging is a highly sensitive technique for assessment of tumor burden, response to therapy, tumor recurrence, and behavior to salvage therapy, making it a superior option for longitudinal monitoring in intracranial rodent models of primary brain tumors.